Premium
Failure to maintain the suppressed level of serum testosterone during luteinizing hormone‐releasing hormone agonist therapy in a patient with prostate cancer
Author(s) -
Kinouchi Toshiaki,
Maeda Osamu,
Ono Yutaka,
Meguro Norio,
Kuroda Masao,
Usami Michiyuki
Publication year - 2002
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.2002.00476.x
Subject(s) - leuprorelin , medicine , goserelin , testosterone (patch) , prostate cancer , castration , luteinizing hormone , agonist , endocrinology , hormone , urology , cancer , gonadotropin releasing hormone , receptor
A 75‐year‐old man with metastatic prostate cancer had been treated with goserelin acetate, and prostate specific antigen (PSA) had decreased, but 1 1 / 2 years after beginning the treatment of goserelin acetate, PSA was markedly elevated and serum testosterone was at normal level. After castration the serum testosterone was at castrate level and PSA decreased. In the present case, leuprorelin acetate 1‐month depot suppressed the luteinizing hormone level in 1 month, even after the patient underwent castration.